|
Match
|
Document |
Document Title |
|
|
US20170119860 |
ENZYME TREATMENT OF FOODSTUFFS FOR CELIAC SPRUE
Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects... |
|
|
US20140227358 |
ORGANIC COMPOUNDS
The present invention provides various pharmaceutical compositions comprising an S1P receptor modulator, e.g. an S1P receptor agonist. In one aspect, there is provided a pharmaceutical composition... |
|
|
US20130295173 |
COMPOSITIONS OF STATINS AND OMEGA-3 FATTY ACIDS
The present disclosure provides pharmaceutical compositions of statins and polyunsaturated fatty acids (PUFAs), in which the statins are dissolved in the PUFAs, the PUFA species being present... |
|
|
US20130202696 |
Agent for use in the case of fructose intolerance
There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose... |
|
|
US20120237599 |
ENTERICALLY COATED CYSTEAMINE, CYSTAMINE AND DERIVATIVES THEREOF
The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release... |
|
|
US20100221329 |
FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE
The invention provides novel formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use in the treatment of gastrointestinal diseases and disorders, including... |
|
|
US20100172976 |
METHODS AND COMPOSITIONS FOR INHIBITING THE FUNCTION OF POLYNUCLEOTIDE SEQUENCES
A therapeutic composition for inhibiting the function of a target polynucleotide sequence in a mammalian cell includes an agent that provides to a mammalian cell an at least partially... |
|
|
US20080274177 |
CONTROLLED RELEASE DOSAGE FORMS
The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55°... |
|
|
US20080152704 |
Dosage Forms of Palonosetron Hydrochloride Having Improved Stability and Bioavailability
Provided are solid oral dosage forms of palonosetron hydrochloride, methods of using the dosage forms to treat emesis, and methods of making the dosage forms. The dosage forms have improved... |
|
|
US20080131501 |
Enhanced immediate release formulations of topiramate
The present invention provides enhanced immediate release formulations of topiramate, in which 80% of the active ingredient is released in the period of time of not more than 30 min. These... |
|
|
US20170014436 |
Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and type 2 diabetes.
The invention provides pharmaceutical compositions, methods for the treatment of, and related diagnostics and computer-implementable systems that relate to, the treatment of a variety of metabolic... |
|
|
US20150238545 |
PROBIOTIC RECOLONISATION THERAPY
The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in... |
|
|
US20150216821 |
ABUSE-PROOFED ORAL DOSAGE FORM
The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which... |
|
|
US20150086625 |
NUTRACEUTICALS CONTAINING NITRO FATTY ACIDS
Activated fatty acids, nutraceutical compositions including activated fatty acids, methods for using activated fatty acids to treat a variety of diseases, and methods for preparing activated fatty... |
|
|
US20150024046 |
ABUSE-PROOFED ORAL DOSAGE FORM
The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which... |
|
|
US20140242163 |
AMANTADINE COMPOSITIONS AND METHODS OF USE
Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine... |
|
|
US20140147499 |
ABUSE-PROOFED ORAL DOSAGE FORM
The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which... |
|
|
US20130243855 |
Modified coagulation factor IX polypeptides and use thereof for treatment
Provided are modified factor IX (FIX) polypeptides and methods of generating modified FIX polypeptides. Also provided are pharmaceutical compositions, including compositions formulation for oral... |
|
|
US20080233185 |
Fumaric Acid Derivatives as NF-kappaB Inhibitor
The present invention relates to the use of one or more fumaric acid derivatives as NF-kappaB inhibitor. At the same time, the present invention relates to the use of the fumaric acid derivatives... |
|
|
US20080075770 |
HYDROPHILIC ABUSE DETERRENT DELIVERY SYSTEM
Disclosed herein are oral dosage forms of therapeutic agents that are resistant to abuse and methods of their formulation. In particular, oral dosage forms that are resistant to dissolution in... |
|
|
US20080063703 |
Active Drug Delivery in the Gastrointestinal Tract
Apparatus (30) for drug administration is provided, including an ingestible capsule (32), which includes a drug (36), stored by the capsule (32), and an environmentally-sensitive mechanism (18),... |
|
|
US20080031941 |
Gastric acid secretion inhibiting composition
An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid susceptible proton pump inhibitor or a salt thereof, an H2 receptor antagonist or a salt thereof and a... |
|
|
US20150118297 |
Prebiotic Formulations and Methods of Use
The invention provides methods and pharmaceutical compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein... |
|
|
US20120045509 |
MODIFIED RELEASE COMPOSITIONS FOR DPP-IV INHIBITORS
The present invention refers to pharmaceutical composition comprising a DPP-IV inhibitor. |
|
|
US20150335715 |
METHODS AND COMPOSITIONS FOR TREATING NAFLD, HEPATIC STEATOSIS, AND SEQUELAE THEREOF
Provided herein are oral pharmaceutical compositions containing a GLP-1 analogue and/or insulin for treating and reducing the incidence of nonalcoholic fatty liver disease (NAFLD), hepatic... |
|
|
US20150140092 |
COATED DRUG DELIVERY FORMULATIONS
The invention relates generally to methods of making formulations for delivering biological agents to a patient. In one aspect, proliposomal drug-delivery systems for medicaments are provided. In... |
|
|
US20130236541 |
PHARMACEUTICAL COMBINATION COMPRISING AN IBAT INHIBITOR AND A BILE ACID BINDER
The present invention relates to a combination comprising a substance with inhibiting effect on the ileal bile acid transport system (I BAT) and at least one other active substance selected from... |
|
|
US20130078305 |
Pharmaceutical Compositions For The Coordinated Delivery Of NSAIDs
The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The... |
|
|
US20090291134 |
ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF PSYCHIATRIC AND NEURODEGENERATIVE DISEASES
The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and... |
|
|
US20080075771 |
HYDROPHILIC OPIOID ABUSE DETERRENT DELIVERY SYSTEM USING OPIOID ANTAGONISTS
Disclosed herein are oral dosage forms of opioid therapeutic agents that are resistant to abuse and methods of their formulation. In particular, oral dosage forms that are resistant to dissolution... |
|
|
US20100285121 |
Capsule Formulation
The present invention provides the following capsule preparation, which is superior in dissolution property and the like of a pharmaceutically active ingredient and contains liquid and solid... |
|
|
US20090196921 |
Compositions Methods and Kits For Enhancing Immune Response To A Respiratory Condition
Disclosed herein are compositions for treating a respiratory condition, preferably by enhancing immune response in a mammal, the compositions including a therapeutic amount of a probiotic strain... |
|
|
US20090117180 |
STABLE DIGESTIVE ENZYME COMPOSITIONS
Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies.... |
|
|
US20080311192 |
Enteric-Coated Glucosinolates And Beta-Thioglucosidases
The present invention relates to a particulate composition comprising enteric-coated glucosinolate and beta-thioglucosidase particles. The present invention further provides a method of converting... |
|
|
US20080206324 |
PELLETS HAVING AN ACTIVE COMPOUND MATRIX AND A POLYMER COATING, AND A PROCESS FOR THE PRODUCTION OF THE PELLETS
An active compound-containing pellet has a polymer coating of an anionic (meth)acrylate copolymer and a pharmaceutically active substance, embedded in a polymer matrix of one or more polymers, a... |
|
|
US20080020018 |
Combination Products
A pharmaceutical formulation comprises a plurality of seamless minicapsules having a diameter of from 0.5 mm to 5 mm, at least some of the minicapsules containing a methyxanthine as one active... |
|
|
US20070259037 |
Method and composition for treatment of inflammatory conditions
Methods of treating inflammation of the gastrointestinal tract and/or systemic or local inflammation by administering a steroid anti-inflammatory or a non-steroid anti-inflammatory drug in... |
|
|
US20150104507 |
FORMULATION OF LACOSAMIDE
A modified release formulation of lacosamide. |
|
|
US20150064248 |
ABUSE RESISTANT FORMS OF EXTENDED RELEASE HYDROMORPHONE, METHOD OF USE AND METHOD OF MAKING
An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier... |
|
|
US20150064247 |
ABUSE RESISTANT FORMS OF IMMEDIATE RELEASE HYDROCODONE, METHOD OF USE AND METHOD OF MAKING
An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier... |
|
|
US20140322317 |
CONTROLLED RELEASE COMPOSITIONS
An improved composition for controlling the release profile of an active compound through the intestinal tract comprises particles, especially pellets, containing the active compound, which are... |
|
|
US20140010872 |
ORAL COMPLEX COMPOSITION COMPRISING OMEGA-3 FATTY ACID ESTER AND HMG-COA REDUCTASE INHIBITOR
An oral complex composition comprising omega-3 fatty acid esters and HMG-CoA reductase inhibitor, can effectively raise serum HDL level while reducing serum LDL and TG levels and can be used to... |
|
|
US20130230588 |
CONTROLLED RELEASE COMPOSITIONS
An improved composition for controlling the release profile of an active compound through the intestinal tract comprises particles, especially pellets, containing the active compound, which are... |
|
|
US20120244216 |
COATED PHARMACEUTICAL CAPSULE DOSAGE FORM
Pharmaceutical compositions in unit dose form comprising a hard or soft capsule containing a fill consisting of one or more inert ingredients, and one or more coatings on the capsule, wherein at... |
|
|
US20110182986 |
CONTROLLED RELEASE COMPOSITION
An improved composition for controlling the release profile of an active compound through the intestinal tract comprises particles, especially pellets, containing the active compound, which are... |
|
|
US20100040678 |
ORGANIC COMPOUNDS
The present invention provides various pharmaceutical compositions comprising an S1P receptor modulator, e.g. an S1P receptor agonist. In one aspect, there is provided a pharmaceutical composition... |
|
|
US20080317725 |
COMPOSITIONS AND METHODS OF TREATING CHRONIC KIDNEY DISEASE
The invention relates to nutritional compositions and methods of using these compositions for the treatment of renal disease. More particularly, the invention discloses compositions of vitamins,... |
|
|
US20150218198 |
NOVEL HYDROXYALKYL METHYL CELLULOSE ACETATE SUCCINATES
Novel hydroxyalkyl methyl cellulose acetate succinates which a) have from 4.0 to less than 10.0 weight percent of succinoyl groups, b) have a weight average molecular weight Mw of from 80,000... |
|
|
US20150098992 |
COMPOSITE FORMULATION COMPRISING MULTI-UNIT SPHEROIDAL TABLET (MUST) ENCAPSULATED IN HARD CAPSULE AND METHOD FOR PREPARING SAME
Provided is a composite formulation comprising multi-unit spheroidal tablets (MUSTs) encapsulated in a hard capsule and a method for preparing same. The inventive hard capsule composite... |
|
|
US20070243244 |
Methods of treating gastrointestinal tract infections with tigecycline
Disclosed herein are methods of treating at least one bacterial infection, such as lower gastrointestinal infections, comprising orally administering a pharmaceutical composition comprising... |